Supporting this clinical activity in patients with Myc‐driven disease, preclinical work with fimepinostat demonstrated Myc protein downregulation in models of diffuse large B‐cell lymphoma and NUT midline carcinomas and significant anti‐tumor activity [19]. Here, MYC is linked to diffuse large B-cell lymphoma.